After helping advance research that contributed to two first-of-their-kind FDA-approved treatments, UCSF’s Pediatric Neuro-Oncology Consortium is expanding its global effort to find better treatments for some of the rarest childhood brain cancers.
Researchers in UCSF’s Radiology and Biomedical Imaging highlight some of their recent works concerning the application of nuclear medicine to the diagnosis and management of bacterial infections and cancers.
Specialists in brain cancer research and clinical care from UC San Francisco are presenting research findings in cancer neuroscience, neuroimaging, precision and immunotherapy at the 31st annual meeting of the Society for Neuro-Oncology in Philadelphia, Nov. 12 to 15.
Trever Bivona, MD, PhD, UCSF professor of Medicine talks about what people should know about lung adenocarcinoma, how physicians determine the best treatment, and why the genetics of a patient’s tumor increasingly matters.
A UCSF team engineered immune cells to activate exclusively in the brain and attack diffuse midline glioma. It worked in mice and it’s poised for a clinical trial at UCSF.
A new AI-based model can predict where the most common malignant brain cancer is most likely to return after initial surgery, potentially giving doctors a chance to treat it before it becomes visible on MRI.
From prostate and lung cancer to tumors of the central and peripheral nervous systems, scientists look to better assess cancer risk and tailor treatment decisions.